Abstract
The Division of Cancer Treatment (DCT) has as one of its major functions the development and clinical testing of new anticancer drugs. The Cancer Therapy Evaluation Branch of the DCT coordinates and monitors the clinical trials on these new anticancer drugs and is responsible for liaison with the Food and Drug Administration. One of the recent drugs developed and placed into clinical trial by the DCT is cis-platinum(II) diamminedichloride (NSC 119 875). The purpose of this paper is to outline the major steps in the development of a new anticancer drug with emphasis on the techniques of clinical evaluation utilizing the platinum compound as the specific example.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Dixon, R. L.: Laboratory of toxicology. Cancer Chemother. Rep. 2 (3), 61 (1971).
Freireich, E. J., Gehan, E. A., RALL, D. P., SCHMIDT, L. H., SKIPPER, H. E.: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 50, 219 (1966).
Hansen, H. H.: Clinical experience with 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU, NSC 79 037). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 87 (1970).
Muggia, F. M.: Phase I study of 4’ demethyl-epipodophyllotoxin-B-D-thenylidene glycoside (PTG, NSC 122 819). Proc. Amer. Ass. Cancer Res. (Abstr.) 11, 58 (1970).
Pinkel, D.: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853 (1958).
Rosenberg, B., Van Camp, L., Grimley, E. B., Thomson, A. J.: The inhibition of growth on cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J. biol. Chem. 242, 1347 (1967).
Rosenberg, B., Van Camp, L., Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.) 205, 698 (1965).
Rothenberg, L., Terselic, R. A.: Management of the National Cancer Institute’s drug research program through application of the linear array concept. Cancer Chemother. Rep. 54, 303 (1970).
Schein, P. S., DAVIS, R. D., Carter, S., Newman, J., Schein, D. R., RALL, D. A.: The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man. Clin. Pharmacol. Ther. 11, 3 (1970).
Shirkey, H. C.: Drug dosage for infants and children. J. Amer. med. Ass. 193, 443 (1965).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1974 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Carter, S.K., Goldsmith, M. (1974). The Development and Clinical Testing of New Anticancer Drugs at the National Cancer Institute — Example cis-Platinum (II) Diamminedichloride (NSC 119 875). In: Connors, T.A., Roberts, J.J. (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Recent Results in Cancer Research, vol 48. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-49306-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-49306-5_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-49308-9
Online ISBN: 978-3-642-49306-5
eBook Packages: Springer Book Archive